Last reviewed · How we verify
KW-3902IV
At a glance
| Generic name | KW-3902IV |
|---|---|
| Sponsor | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PHASE3)
- PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PHASE3)
- Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy (PHASE3)
- Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment (PHASE2)
- Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KW-3902IV CI brief — competitive landscape report
- KW-3902IV updates RSS · CI watch RSS
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI